Delayed cancer treatment reduces survival 

Advanced Lung Cancer Study Suggests Liquid Biopsy Reduces Treatment Delays, Boosts Target Detection

science

A clinical trial suggests circulating tumor DNA genotyping prior to tissue-based diagnoses can reduce time to treatment in advanced NSCLC patients.

Genome Web     Jul 25, 2023

Lung Cancer Study Suggests Liquid Biopsy Reduces Treatment Delays, Boosts Target Detection

science

A clinical trial suggests circulating tumor DNA genotyping prior to tissue-based diagnoses can reduce time to treatment in advanced NSCLC patients.

Genome Web     Jul 25, 2023

Study: Blood Cancer Treatment Found to Kill Latent HIV-Infected ... - Pharmacy Times

Although antiretroviral therapies are the standard of care treatment for those with HIV, the drugs cannot target latent infections; however, venetoclax, a blood cancer treatment, shows promise.

pharmacytimes.com     Sep 06, 2023

Delayed diagnosis of cancer: a global overview of loss of chance ... - Kennedys Law

The impact of the pandemic on the number of delayed diagnosis claims, particularly in relation to loss of chance, is yet to be realised, but may be significant. In the jurisdictions explored in our conference, courts have not yet had to consider a COVID-19 resourcing defence. In England, allegations in delayed diagnosis of cancer claims that include elements relating to the pandemic, are starting to come through. This is despite cancer treatment being prioritised during the national lockdowns.

Law.com     Jul 13, 2023

Cost-effectiveness analysis of serplulimab combined with chemotherapy in the treatment of extensive-stage small-cell lung cancer from the perspective of the healthcare system in China

Objective The ASTRUM-005 trial showed that serplulimab plus chemotherapy (SEP) significantly extended survival time compared with chemotherapy in the treatment of small cell lung cancer. But the survival benefits of SEP came at high costs, and its economy is not clear. Therefore, this study aimed to evaluate the cost-effectiveness of SEP from the perspective of the Chinese healthcare system. Design A partition survival model was built to simulate the outcomes. The clinical data came from the ASTRUM-005 trial, and only direct medical costs were included in the model. The utility values referred to the published literature. Scenario analyses 1 and 2 explored outcomes in the presence of a patient assistance plan (PAP) and different simulation periods, ...

BMJ     Aug 17, 2023

Work-related experiences of prostate cancer survivors in Australia: a ... - BMC Public Health

Prostate cancer (PCa) is the most diagnosed cancer in Australian men, and the number of survivors is growing with advances in diagnosis and treatment. Work participation following PCa diagnosis and treatment becomes a significant aspect of quality of life and survivorship. Using a qualitative phenomenological approach, we explored the work-related experiences of PCa survivors in Australia.

bmcpublichealth.biomedcentral.com     Sep 16, 2023

😊 Kettering Health Elevates Prostate Cancer Treatment with First-of-its ... - Kettering Health

Kettering Health is a faith-based family of medical centers, emergency centers, and outpatient facilities. Our mission is to empower you to be your best.

ketteringhealth.org     Sep 12, 2023

Single-arm, phase II study of intra-arterial chemotherapy plus total neoadjuvant therapy to optimise complete response in distal rectal cancer: a study protocol

Introduction Organ preservation is now considered an acceptable alternative option in distal rectal cancer patients with clinical complete response (cCR) after neoadjuvant chemoradiation (CRT). But the cCR rate is low and about one-third of tumour will regrow, which requires more effective local treatment. CRT combined with intra-arterial chemotherapy (IAC) might be a promising approach. Additionally, total neoadjuvant therapy using FOLFIRINOX induction chemotherapy improved survival while consolidation chemotherapy improved organ preservation. We assess whether IAC plus CRT and FOLFIRINOX consolidation chemotherapy can improve the chance of organ preservation and survival in distal rectal cancer. Methods and analysis This prospective, monocentric, open-label, single-arm phase II study will include 32 patients with cT3-4NanyM0 distal rectal adenocarcinoma.

BMJ     Oct 05, 2023

PDS Biotech Announces Updated Survival Data from NCI-Led ... - BioSpace

PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell activating platforms, today announced updated survival data from the Phase 2 clinical trial investigating the triple combination of PDS0101, PDS0301 (IL-12 antibody-drug conjugate) and an investigational immune checkpoint inhibitor (ICI) in two groups of advanced cancer patients with various types of human papillomavirus (HPV) 16-positive cancers. The ICI naïve group had not responded to standard-of-care treatments but had not yet been treated with an ICI.

biospace.com     Nov 09, 2023

Association of Race, Ethnicity, Language, and Insurance with Time to Treatment Initiation Among Women with Breast Cancer at an Urban, Academic, Safety-Net Hospital

science

CONCLUSION: At our institution, race, ethnicity, insurance, and language were not associated with treatment delay. Additional research is needed to determine how our safety-net hospital delivered timely care to all patients with breast cancer, as reducing delays in care may be one mechanism by which health systems can mitigate disparities in the treatment of breast cancer.

NCBI     Nov 28, 2023

Medicina, Vol. 59, Pages 1923: In Silico and In Vitro Exploration of Poziotinib and Olmutinib Synergy in Lung Cancer: Role of hsa-miR-7-5p in Regulating Apoptotic Pathway Marker Genes

Background and objectives: Non-small cell lung cancer (NSCLC) is often caused by EGFR mutations, leading to overactive cell growth pathways. Drug resistance is a significant challenge in lung cancer treatment, affecting therapy effectiveness and patient survival. However, combining drugs in research shows promise in addressing or delaying resistance, offering a more effective approach to cancer treatment. In this study, we investigated the potential alterations in the apoptotic pathway in A549 cells induced by a combined targeted therapy using tyrosine kinase inhibitors (TKIs) olmutinib and poziotinib, focusing on cell proliferation, differential gene expression, and in silico analysis of apoptotic markers. Methods: A combined targeted therapy involving olmutinib and poziotinib was investigated for its impact on the apoptotic pathway ...

mdpi.com     Oct 30, 2023

Evaluating Implementation Strategies for Tobacco Use Treatment in ... - Feinberg News Center

Electronic health record-based messages delivered solely to clinicians increased referral to tobacco use treatment for cancer patients who smoke, according to a recent study published in the Journal of Clinical Oncology.

news.feinberg.northwestern.edu     Sep 01, 2023

Protocol for the EACH trial: a multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any line treatment for patients with recurrent/metastatic head and neck squamous cell cancer (HNSCC) in the UK

Introduction Head and neck cancer is the eighth most common cancer in the UK. Current standard of care treatment for patients with recurrent/metastatic squamous cell head and neck carcinoma (HNSCC) is platinum-based chemotherapy combined with the anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibody, cetuximab. However, most patients will have poor median overall survival (OS) of 6–9 months despite treatment. HNSCC tumours exhibit an immune landscape poised to respond to immunotherapeutic approaches, with most tumours expressing the immunosuppressive receptor programmed death-ligand 1 (PD-L1). We undertook the current study to determine the safety and efficacy of avelumab, a monoclonal antibody targeting the interaction between PD-L1 and its receptor on cytotoxic T-cells, in combination with cetuximab.

BMJ     Nov 28, 2023

Cancers, Vol. 15, Pages 3482: Comparative In Silico Analysis of Ultra-Hypofractionated Intensity-Modulated Photon Radiotherapy (IMRT) Versus Intensity-Modulated Proton Therapy (IMPT) in the Pre-Operative Treatment of Retroperitoneal Sarcoma

Background: While pre-operative radiation did not improve abdominal recurrence-free survival for retroperitoneal sarcoma (RPS) in the randomized STRASS trial, it did reduce rates of local recurrence. However, the risk of toxicity was substantial and the time to surgery was prolonged. A combination of hypofractionation and proton therapy may reduce delays from the initiation of radiation to surgery and limit the dose to surrounding organs at risk (OARs). We conducted a dosimetric comparison of the pre-operative ultra-hypofractionated intensity-modulated photon (IMRT) and proton radiotherapy (IMPT). Methods: Pre-operative IMRT and IMPT plans were generated on 10 RPS patients. The prescription was 25 Gy radiobiological equivalents (GyEs) (radiobiological effective dose of 1.1) to the clinical target volume and 30 GyEs to ...

mdpi.com     Jul 04, 2023

PDS Biotech Announces Interim 24-Month Survival Rate of 74% in ... - BioSpace

PRINCETON, N.J., Oct. 03, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell activating platforms, today announced updated interim data based on an August 2nd cut off from the VERSATILE-002 Phase 2 clinical trial evaluating PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with unresectable, recurrent, or metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC). VERSATILE-002 is investigating two patient populations whose cancer has returned or spread – ICI naïve and ICI refractory.

biospace.com     Oct 03, 2023

Lung cancer research: five advancements over the past year - Labiotech.eu

Lung cancer is the second most common cancer worldwide, with more than 2.2 million new cases of lung cancer being reported in 2020. Survival rates depend on the stage of diagnosis, and, according to statistics from Cancer Research UK, in England, more than 55% of people with stage 1 lung cancer survive for five years or more, compared to only around 5% of people with advanced, stage 4 lung cancer.

labiotech.eu     Jul 10, 2023